An Analysis of the Results of the BETH Study

Adam Brufsky, MD, PhD, FACP, professor of medicine, associate division chief, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, discusses the results of the BETH study, which compared chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus bevacizumab in patients with HER2-positive breast cancer.

Clinical Pearls:

• Although the results of the trial were negative, the results did show that THC therapy is as good, if not better, than ACTH therapy
• The results of the BETH study are consistent with other studies
• The era of adjuvant bevacizumab for breast cancer has come and gone unless there is a way to select patients who will benefit
• Some biomarkers are in the works that may be able to be used to select patients who will benefit from bevacizumab